AMPH Amphastar Pharmaceuticals
- 41.110
- +0.280+0.69%
Amphastar Pharmaceuticals News
Institutional Investors Control 67% of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) and Were Rewarded Last Week After Stock Increased 5.6%
Key Insights Given the large stake in the stock by institutions, Amphastar Pharmaceuticals' stock price might be vulnerable to their trading decisions A total of 8 investors have a majority stake in
Amphastar Pharmaceuticals Poised for Growth: Strong Generic Pipeline and Strategic Marketing Drive Buy Rating
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shareholders YoY Returns Are Lagging the Company's 66% Three-year Earnings Growth
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Ascendis Pharma (ASND) and AMN Healthcare Services (AMN)
Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies
At the Needham Healthcare Conference, Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) highlighted why they remain excited about Baqsimi, the inhaled glucagon product for severe hypoglycemia. Amphastar Pha
Express News | Needham Reiterates Hold on Amphastar Pharma
Needham Sticks to Its Hold Rating for Amphastar Pharmaceuticals (AMPH)
Amphastar Pharmaceuticals (NASDAQ:AMPH) Offers Savvy Value Investors a Window of Opportunity
Amphastar Pharmaceuticals (AMPH) Stock Moves -1%: What You Should Know
If EPS Growth Is Important To You, Amphastar Pharmaceuticals (NASDAQ:AMPH) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage
Amphastar Pharmaceuticals(AMPH.US) Director Sells US$21,714.15 in Common Stock
$Amphastar Pharmaceuticals(AMPH.US)$ Director Petersen Floyd F. sold 500 shares of Common Stock on Apr 1, 2024 at an average price of $43.4283 for a total value of $21,714.15.Source: Announcement What
Amphastar Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 1, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations,
Amphastar Pharmaceuticals (AMPH) Stock Sinks As Market Gains: What You Should Know
Amphastar Pharmaceuticals (NASDAQ:AMPH) Seems To Use Debt Quite Sensibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' It's only natural to consider a company's balance sheet wh
Amphastar Pharmaceuticals Inc CFO, EVP & Treasurer William Peters Sells 18,136 Shares
Amphastar Pharmaceuticals Insider Sold Shares Worth $842,883, According to a Recent SEC Filing
William J Peters, Director, CFO, Executive Vice President & Treasurer, on March 06, 2024, sold 18,136 shares in Amphastar Pharmaceuticals (AMPH) for $842,883. Following the Form 4 filing with the SEC,
Teva Upgraded at J.P. Morgan on Upcoming Catalysts
Amphastar Pharmaceuticals(AMPH.US) Director Sells US$589.72K in Common Stocks
$Amphastar Pharmaceuticals(AMPH.US)$ Director ZASLOFF MICHAEL A sold 12,500 shares of Common Stocks on Mar 5, 2024 at an average price of $47.1779 for a total value of $589.72K.Source: Announcement Wh
Amphastar Pharmaceuticals to Present at the Barclays 26th Annual Global Healthcare Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / March 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operation
Amphastar a New Overweight at J.P. Morgan on Diverse Asset Portfolio
Analysis
Price Target
No Data
